Larvol Delta - Envudeucitinib-ESK001-in-moderatetosevere-plaque-psoriasis-24week-results-from-the-randomized-doubleblind-active-comparator-and-placebocontrolled-Phase-3-ONWARD1-and-2-studies

envudeucitinib (ESK-001) - Alumis

https://pagv3.virtual-meeting.org/eadv/eadvcongress2026/en-GB/pag/presentation/63294

Andrew Blauvelt

Aug 6, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next